Physician profile
Cole Garrett Locklear
NPI 1972959211
$1,503.38
in general payments reported to CMS, 2019-2025
20 companies · $1,182 in 2025
The $1,182 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $322 · 2025: $1,182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,503.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,503.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $377.74 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $313.68 | 2025 | |
| Lilly USA, LLC | $132.03 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $80.02 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.98 | 2024-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.10 | 2025 | Jardiance |
| Cequr Corporation | $64.04 | 2025 | Cequr Simplicity |
| Otsuka America Pharmaceutical, INC. | $51.30 | 2025 | Rexulti |
| Exact Sciences Corporation | $49.47 | 2024-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $46.82 | 2024-2025 | |
| Inspire Medical Systems, INC. | $44.13 | 2024 | Inspire |
| Abbott Laboratories | $42.17 | 2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $31.24 | 2024 | Spravato |
| Dynavax Technologies Corporation | $27.52 | 2025 | Heplisav-B |
| Abbvie INC. | $24.17 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $20.33 | 2025 | Capvaxive |
| Shield Therapeutics INC | $19.45 | 2025 | |
| Astellas Pharma US INC | $17.80 | 2025 | Veozah |
| Eisai INC. | $14.73 | 2025 | |
| Sumitomo Pharma America, INC. | $13.66 | 2024 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cole Locklear listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.